{"entity":{"id":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","kind":"paper","name":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","aka":[],"tldr":"Adding a single course of the bispecific antibody blinatumomab after induction chemotherapy in infants with KMT2A-rearranged leukaemia raised two-year disease-free survival from a historical 49 percent to 82 percent, the first major advance in infant leukaemia in decades.","summary":"Single-arm phase 2 study of 30 infants with newly diagnosed KMT2A-rearranged ALL treated on the Interfant-06 backbone with one 28-day course of blinatumomab after induction, compared with historical Interfant-06 controls.\n\nTwo-year disease-free survival was 81.6 percent against 49.4 percent historically, overall survival 93.3 versus 65.8 percent, and blinatumomab was well tolerated with no treatment discontinuations for toxicity; measurable residual disease became negative or low in almost all infants.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2023","url":"https://doi.org/10.1056/NEJMoa2214171"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37099340/"}],"tags":[],"related":[],"cancers":["all-infant"],"sections":[],"technologies":[],"targets":[],"drugs":["blinatumomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/NEJMoa2214171","pmid":"37099340","authors":"van der Sluis IM, de Lorenzo P, Kotecha RS, et al.","paperType":"observational","findings":["Two-year disease-free survival 81.6 percent vs 49.4 percent in historical controls.","Two-year overall survival 93.3 percent vs 65.8 percent."],"whatItMeans":"Blinatumomab after induction is now standard for KMT2A-rearranged infant ALL through the Interfant-21 protocol.","caveats":["Thirty patients with historical comparison; longer follow-up needed."],"changedPractice":true,"participants":30},"route":"/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/","neighbours":{"cancer":[{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}